Risk factors
Monopar Therapeutics (MNPR) risk factors
Item 1A of every Monopar Therapeutics 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors82 risks2 dropped12 reworded
Monopar's updated risk disclosures reflect higher accumulated losses, expanded share counts, and updated patent and tariff details for the ALXN1840 program.
Filed Mar 27, 2026 - FY2024 10-K risk factors84 risks
Monopar relies heavily on its ability to finance and develop its lead assets, particularly ALXN1840 and MNPR-101. The company faces high regulatory hurdles, reliance on third-party suppliers, and uncertainties in clinical trials and future commercialization.
Filed Mar 31, 2025